Stayble Therapeutics AB
3 Feb - 17 Feb 2021Rights issue
Discogenic Chronic Low Back Pain (cLBP) is a disabling disease for patients, and an extremely expensive condition for society. Today, spinal fusion is the only available treatment for patients who do not respond to analgesics and physiotherapy. Stayble Therpeutics AB:s solution that has been evaluated in a clinical phase 1b trial, aims at changing that.
Stayble’s injectable formulation STA363 targets patients suffering from discogenic chronic low back pain who do not respond to conservative treatment such as analgesics and physiotherapy. STA363 not only offers patients an option when conservative treatment fails but also provides an alternative for patients who cannot afford, are not eligible or do not want to have spinal fusion surgery.
The offer in summary
Record date: 29 January 2021
Subscription period: 3 February - 17 February 2021
Trading in subscription rights: 3 February – 15 February 2021
Terms: Shareholders in Euroclear by the record date 29 January 2021 will obtain one (1) subscription right per existing share. To subscribe for one (1) new share, one (1) subscription right are required to be exercised
Subscription price: SEK 6.00
Payment day: Payment and subscription form shall be Nordic Issuing at hand no later than 17 February 2021
Share ISIN: SE0013513652
Finacial adviser: Sedermera Fondkommission
Trading in BTA: 3 February 2021 - until the rights issue has been registered with the Swedish Companies Registration Office, which is expected to take place in the middle of March 2021
Those who on the record date of January 29, 2021 are registered as shareholders in Stayble Therapeutics AB have a preferential right to subscribe for shares in the current new share issue. For each existing share, one (1) subscription right is received. Each subscription right entitles the holder to subscribe for one (1) new share. The last day for trading in the share, including the right to receive subscription rights, is January 27, 2021. The first day for trading in the share, excluding the right to receive subscription rights, is January 28, 2021.
The offer comprises a maximum of 6,923,462 shares, corresponding to approximately MSEK 41.5.